Company snapshot
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With our unique expertise in understanding the interaction of light and human skin, we have identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million.
Clinuvel’s lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), is in Phase II and III trials in the US and Europe, and is expected to be filed before the end of 2011 for review by the European Medicines Agency. Presently, there is no known effective treatment for EPP and SCENESSE® has been granted orphan drug status. Based in Melbourne, Australia, Clinuvel has operations in Europe and in the US, with 25 employees worldwide.
|
|
|
|
|
Facts |
ASX Listed Shares on Issue Options (unlisted) Conditional performance rights Top 50 own 52 weeks price range Market cap (1/12/2011) Employees |
2001 30,394,209 1,168,000 3,072,750 69.25% $1.40 - $2.37 A$44.07m 25 |
|
Locations |
Melbourne, Australia Baar, Switzerland Jersey City, USA |
Company headquarters European operational office US operational office |
|
Stock listings |
ASX Xetra-DAX Level 1 ADR |
CUV UR9 CLVLY |
|
Finances |
Cash/assets at bank (30/09/2011) Monthly spend rate (av. Q3 ’11) |
A$14.604m A$1.209m |
|
Products |
First-in-class photoprotective and repigmentation drug currently in Phase II and III trials Alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue in early development |
|
|
People |
Chair CEO, Director Chief Scientific Officer, Director Non-Executive Director Non-Executive Director Non-Executive Director VP, Scientific Affairs CFO, Company Secretary |
|
|
Contact |
General Investors |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
Last updated: December 1, 2011
